SC Pharmaceuticals(002693.SZ)

Last Updated 00:00:00
longbridge loading
Company Encyclopedia
View More
name
SC Pharmaceuticals
002693.SZ
Hainan Shuangcheng Pharmaceuticals Co., Ltd. engages in research and development, production, and sale of pharmaceutical injections, solid preparations, and raw materials in China and internationally. The company offers products for oncology and immune, alimentary canal, heart and cerebral, and vessels and metabolism. It also provides Bivalirudin, Epitifibatide, and Thymalfaxin for injection; Pregabalin capsule; and Memantine Hydrochloride tablets and Pioglitazone tablets USP.
2.568 T
002693.SZMarket value -Rank by Market Cap -/-

Financial Score

14/06/2026 Update
B
PharmaceuticalsIndustry
Industry Ranking56/222
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE8.14%B
    • Profit Margin11.28%B
    • Gross Margin62.35%A
  • Growth ScoreA
    • Revenue YoY71.62%A
    • Net Profit YoY140.87%A
    • Total Assets YoY7.07%B
    • Net Assets YoY5.48%C
  • Cash ScoreA
    • Cash Flow Margin264.30%A
    • OCF YoY71.62%A
  • Operating ScoreC
    • Turnover0.37C
  • Debt ScoreC
    • Gearing Ratio48.55%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    ST SC Pharmaceuticals: Passed the drug GMP compliance inspection

    Zhitong·
    SZ
    002693
    +1.89%
    Zhitong·
    SZ
    002693
    +1.89%

    ST SC Pharmaceuticals released its half-year performance, with a net loss attributable to shareholders of 18.4666 million yuan, an increase of 8.97%

    Zhitong·
    SZ
    002693
    +1.89%
    Zhitong·
    SZ
    002693
    +1.89%

    ST SC Pharmaceuticals: Eptinezumab injection has obtained marketing authorization from the Therapeutic Goods Administration (TGA) of Australia

    Zhitong·
    SZ
    002693
    +1.89%
    Zhitong·
    SZ
    002693
    +1.89%

    ST SC Pharmaceuticals: Injectable Paclitaxel (Albumin-Bound) ANDA approved for market by the U.S. FDA

    Zhitong·
    SZ
    002693
    +1.89%
    Zhitong·
    SZ
    002693
    +1.89%

    ST SC Pharmaceuticals: Injectable Bivalirudin has obtained market approval from the Therapeutic Goods Administration (TGA) of Australia

    Zhitong·
    SZ
    002693
    +1.89%
    Zhitong·
    SZ
    002693
    +1.89%
    © 2026 Longbridge｜Disclaimer